Maxim lowered the firm's price target on Nuvini to $8 from $70 and keeps a Buy rating on the shares. Nvni is well-positioned for 2026 with high recurring revenue and added growth from M&A, while thefirm also expects additional M&A in Brazil and more broadly in Latin America given a less competitive market, management's track record, and synergy potential, the analyst tells investors in a research note. Due to capital needs and compounded by the depressed stock price, the firm is increasing its share count forecast, which results in incremental dilution and a lower price target, Maxim added.
